Biocryst Pharma Inc (BCRX)

$7.08 +0.18 (2.61%)
Market Cap 1.51B
Revenue (ttm) 450.71M
Net Income (ttm) -88.88M
EPS (ttm) N/A
PE Ratio 90.38
Forward PE 38.39
Profit Margin -19.72%
Debt to Equity Ratio -1.73
Volume 3,678,522
Avg Vol 5,112,782
Day's Range N/A - N/A
Shares Out 210.54M
Stochastic %K 48%
Beta 1.09
Analysts Strong Sell
Price Target $19.73

Company Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and injectable protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phas...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 919 859 1302
Fax: 919 859 1314
Address:
4505 Emperor Boulevard, Suite 200, Durham, United States
Uptrending21
Uptrending21 Nov. 14 at 6:51 PM
$BCRX Adding at 7.07.
1 · Reply
Fergus20
Fergus20 Nov. 14 at 5:32 PM
$BCRX $SRRK yes congrats. It popped but is still in an insanely bearish pattern. Sell now.
2 · Reply
Thinkingman91
Thinkingman91 Nov. 14 at 5:31 PM
$BCRX any of you catch the $SRRK move? Ima leave yall alone
2 · Reply
Fergus20
Fergus20 Nov. 14 at 5:30 PM
$BCRX needs to close above $7.32 for any hope.
1 · Reply
Fergus20
Fergus20 Nov. 14 at 5:30 PM
$BCRX time for bye bye.
1 · Reply
2YrsEarly
2YrsEarly Nov. 14 at 5:21 PM
$BCRX Another anemic volume pump and still down on the week as XBI and markets rip once again. Technicals all bearish 50 day and longer. Gonna need a positive catalyst to catch shorts by surprise with huge volume. Until then we they remain in firm control.
1 · Reply
Fergus20
Fergus20 Nov. 14 at 5:13 PM
$BCRX just drop it back down already. Enough teasing.
1 · Reply
milt0n
milt0n Nov. 14 at 5:03 PM
$BCRX Final results from Alpha-Star Phase 1B/2 trial of Navenibart just published in the November issue of Annals of Allergy, Asthma & Immunology. https://www.sciencedirect.com/science/article/abs/pii/S1081120625005204 Results: No severe or serious TEAEs were reported; no TEAEs led to discontinuation. The mean (median) monthly attack rate and moderate or severe attack rates were reduced after treatment, and quality of life score improved. Navenibart robustly and durably decreased the HAE attack rate with a favorable safety profile. Every 3- and 6-month regimens are currently being investigated in a Phase 3 trial (ALPHA-ORBIT, NCT068428).
0 · Reply
Iwillbuy
Iwillbuy Nov. 14 at 4:44 PM
$BCRX big green candles!
0 · Reply
Smnorgy1
Smnorgy1 Nov. 14 at 4:37 PM
$BCRX ThinkingCow's srrk is up 7 bucks today.
0 · Reply
Latest News on BCRX
BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

Nov 6, 2025, 8:00 AM EST - 8 days ago

BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 5, 2025, 7:01 AM EST - 9 days ago

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conference

Nov 5, 2025, 7:00 AM EST - 9 days ago

BioCryst to Present at Upcoming Investor Conference

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

Nov 3, 2025, 12:16 PM EST - 11 days ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 7:00 AM EST - 11 days ago

BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

Oct 23, 2025, 7:00 AM EDT - 22 days ago

BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Oct 20, 2025, 7:00 AM EDT - 25 days ago

BioCryst to Report Third Quarter 2025 Financial Results on November 3

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

Oct 17, 2025, 3:20 PM EDT - 4 weeks ago

Astria Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Astria Therapeutics, Inc. - ATXS

ATXS

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

Oct 14, 2025, 1:16 PM EDT - 4 weeks ago

BioCryst Pharmaceuticals, Inc. (BCRX) M&A Call Transcript

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

Oct 14, 2025, 12:20 PM EDT - 4 weeks ago

BioCryst Says Astria Therapeutics $700 Million Deal Gives 'Perfect Second Product Candidate'

ATXS

BioCryst to buy Astria Therapeutics in $700 million deal

Oct 14, 2025, 7:35 AM EDT - 4 weeks ago

BioCryst to buy Astria Therapeutics in $700 million deal

ATXS

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

Oct 14, 2025, 7:00 AM EDT - 4 weeks ago

BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile

ATXS

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

Oct 1, 2025, 7:00 AM EDT - 6 weeks ago

BioCryst Completes Sale of European ORLADEYO® (berotralstat) Business

BioCryst: Blue Light Special In Small Cap Biotech Aisle

Sep 29, 2025, 2:53 AM EDT - 6 weeks ago

BioCryst: Blue Light Special In Small Cap Biotech Aisle

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript

Sep 5, 2025, 5:47 AM EDT - 2 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Cantor Global Healthcare Conference 2025 Transcript

BioCryst Announces Departure of Dr. Helen Thackray

Aug 11, 2025, 7:00 AM EDT - 3 months ago

BioCryst Announces Departure of Dr. Helen Thackray

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

Aug 4, 2025, 11:38 AM EDT - 3 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2025 Earnings Call Transcript

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 4, 2025, 7:00 AM EDT - 3 months ago

BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

Jul 31, 2025, 7:00 AM EDT - 3 months ago

BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December

BioCryst to Report Second Quarter 2025 Financial Results on August 4

Jul 21, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Report Second Quarter 2025 Financial Results on August 4

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

Jul 9, 2025, 7:00 AM EDT - 4 months ago

BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

Jul 7, 2025, 7:00 AM EDT - 4 months ago

BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

Jun 27, 2025, 7:00 AM EDT - 5 months ago

BioCryst Announces Sale of European ORLADEYO® (berotralstat) Business to Neopharmed Gentili for up to $264 Million

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

Jun 16, 2025, 7:00 AM EDT - 5 months ago

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI

ORLADEYO® (berotralstat) Approved in Colombia

Jun 13, 2025, 7:00 AM EDT - 5 months ago

ORLADEYO® (berotralstat) Approved in Colombia

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

Jun 6, 2025, 7:00 AM EDT - 5 months ago

BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

Jun 2, 2025, 7:00 AM EDT - 5 months ago

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

May 30, 2025, 7:00 AM EDT - 6 months ago

BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages

BioCryst to Present at Upcoming Investor Conferences

May 27, 2025, 7:00 AM EDT - 6 months ago

BioCryst to Present at Upcoming Investor Conferences

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

May 16, 2025, 7:00 AM EDT - 6 months ago

BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO® (berotralstat)

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

May 14, 2025, 7:00 AM EDT - 6 months ago

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

May 5, 2025, 5:29 PM EDT - 6 months ago

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

BioCryst: Strong Opportunity For A Double With A Proven Therapy

May 5, 2025, 2:05 PM EDT - 6 months ago

BioCryst: Strong Opportunity For A Double With A Proven Therapy

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

May 5, 2025, 12:54 PM EDT - 6 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

May 5, 2025, 7:00 AM EDT - 6 months ago

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst Appoints Steve Frank to Board of Directors

May 1, 2025, 7:00 AM EDT - 7 months ago

BioCryst Appoints Steve Frank to Board of Directors

BioCryst to Report First Quarter 2025 Financial Results on May 5

Apr 21, 2025, 7:00 AM EDT - 7 months ago

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst: Orladeyo's Expansion Is Just Getting Started

Feb 26, 2025, 9:09 AM EST - 9 months ago

BioCryst: Orladeyo's Expansion Is Just Getting Started

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

Feb 26, 2025, 7:45 AM EST - 9 months ago

BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

Feb 25, 2025, 6:24 PM EST - 9 months ago

BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

Feb 24, 2025, 12:17 PM EST - 9 months ago

BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

Feb 24, 2025, 11:49 AM EST - 9 months ago

BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

Feb 24, 2025, 7:00 AM EST - 9 months ago

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

Feb 24, 2025, 6:00 AM EST - 9 months ago

BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

Feb 12, 2025, 7:00 AM EST - 9 months ago

BioCryst Launches ORLADEYO® (berotralstat) in Portugal

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

Feb 10, 2025, 8:30 AM EST - 9 months ago

BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

Feb 10, 2025, 7:00 AM EST - 9 months ago

BioCryst to Report Fourth Quarter 2024 Financial Results on February 24

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

Jan 10, 2025, 7:00 AM EST - 11 months ago

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 11 months ago

BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Dec 9, 2024, 1:47 PM EST - 1 year ago

BioCryst Pharmaceuticals: Seasoned Blockbuster Makes It A Buy

Uptrending21
Uptrending21 Nov. 14 at 6:51 PM
$BCRX Adding at 7.07.
1 · Reply
Fergus20
Fergus20 Nov. 14 at 5:32 PM
$BCRX $SRRK yes congrats. It popped but is still in an insanely bearish pattern. Sell now.
2 · Reply
Thinkingman91
Thinkingman91 Nov. 14 at 5:31 PM
$BCRX any of you catch the $SRRK move? Ima leave yall alone
2 · Reply
Fergus20
Fergus20 Nov. 14 at 5:30 PM
$BCRX needs to close above $7.32 for any hope.
1 · Reply
Fergus20
Fergus20 Nov. 14 at 5:30 PM
$BCRX time for bye bye.
1 · Reply
2YrsEarly
2YrsEarly Nov. 14 at 5:21 PM
$BCRX Another anemic volume pump and still down on the week as XBI and markets rip once again. Technicals all bearish 50 day and longer. Gonna need a positive catalyst to catch shorts by surprise with huge volume. Until then we they remain in firm control.
1 · Reply
Fergus20
Fergus20 Nov. 14 at 5:13 PM
$BCRX just drop it back down already. Enough teasing.
1 · Reply
milt0n
milt0n Nov. 14 at 5:03 PM
$BCRX Final results from Alpha-Star Phase 1B/2 trial of Navenibart just published in the November issue of Annals of Allergy, Asthma & Immunology. https://www.sciencedirect.com/science/article/abs/pii/S1081120625005204 Results: No severe or serious TEAEs were reported; no TEAEs led to discontinuation. The mean (median) monthly attack rate and moderate or severe attack rates were reduced after treatment, and quality of life score improved. Navenibart robustly and durably decreased the HAE attack rate with a favorable safety profile. Every 3- and 6-month regimens are currently being investigated in a Phase 3 trial (ALPHA-ORBIT, NCT068428).
0 · Reply
Iwillbuy
Iwillbuy Nov. 14 at 4:44 PM
$BCRX big green candles!
0 · Reply
Smnorgy1
Smnorgy1 Nov. 14 at 4:37 PM
$BCRX ThinkingCow's srrk is up 7 bucks today.
0 · Reply
YerbMe
YerbMe Nov. 14 at 4:23 PM
$BCRX Nice, big candles!
0 · Reply
Iwillbuy
Iwillbuy Nov. 14 at 4:22 PM
$BCRX Glad I added again!
0 · Reply
DontBanMeAgain
DontBanMeAgain Nov. 14 at 2:56 PM
$BCRX I don't see my name on here?
1 · Reply
BillsBowTie
BillsBowTie Nov. 14 at 2:51 PM
$BCRX DME trial starting.... https://clinicaltrials.gov/study/NCT07228559?term=Biocryst&limit=10&aggFilters=status:rec%20act%20not&rank=2
2 · Reply
9930wenmoon
9930wenmoon Nov. 14 at 2:20 PM
$BCRX anyone seeing the feed?
1 · Reply
Iwillbuy
Iwillbuy Nov. 14 at 1:23 PM
$BCRX Added a few this morning… Little at a time until we find the foundation again!
0 · Reply
Fergus20
Fergus20 Nov. 14 at 1:09 PM
$BCRX shaping up to be another perfect day here.
1 · Reply
Saffier1988
Saffier1988 Nov. 14 at 12:57 PM
$BCRX markets crashing again 6,5O
1 · Reply
Paulzk
Paulzk Nov. 14 at 12:54 PM
$BCRX Tech and the Mag 7 getting hit hard today. The stocks everyone wants to own are now the stocks they want to sell.
0 · Reply
Paulzk
Paulzk Nov. 14 at 12:38 PM
$BCRX The blood bath begins
1 · Reply
SNOB_ORDER
SNOB_ORDER Nov. 14 at 12:23 PM
$BCRX The committee recommended granting a marketing authorisation for Dawnzera (donidalorsen), for the routine prevention of recurrent attacks of hereditary angioedema (swelling) in adults and adolescents aged 12 years and older. Patients with hereditary angioedema have attacks of rapid swelling such as in the face, throat, arms and legs, or around the gut.
1 · Reply
2YrsEarly
2YrsEarly Nov. 14 at 2:05 AM
$BCRX The definition of insanity is doing the same thing over and over and expecting a different result. (I’m guilty) The stock was $5.62 in 1994!! Since then a blockbuster drug approved/$600M revenue/company CFP and NOTHING has changed. And then Stonehouse gives a big middle finger to shareholders and gambles the money that should have rightfully been returned to shareholders on a risky phase 3 drug. Can’t make this sh*t up.
1 · Reply